Glibomet

Glibomet is a combined hypoglycemic drug.

Release form and composition

Make tablets Glibomet containing the active ingredients:

• Metformin hydrochloride - 400 mg;
• Glibenclamide - 2.5 mg.

Magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, glycerol, gelatin, corn starch, talc act as auxiliary substances of Glibomet.

In blister packs of 20 tablets.

Indications for use

According to the instructions, Glibomet is indicated for use in diabetes mellitus type 2 in case of treatment failure with bigunides and sulfonylurea derivatives, as well as other hypoglycemic drugs.

Contraindications

According to the instructions, Glibomet is prohibited for use in the following cases:

• Type 1 diabetes;
• Lactic acidosis;
• Gestational diabetes;
• Diabetic precoma, coma, diabetic ketoacidosis;
• Severe abnormal liver function;
• Conditions resulting from the development of hypoglycemia and impaired absorption of food;
• Acute conditions that cause impaired renal function (severe infection, dehydration, intravascular administration of contrast iodine-containing substances, shock);
• Conditions causing hypoxia (respiratory or heart failure, shock, recent myocardial infarction, severe pathologies of the respiratory tract);
• Severe renal failure;
• The period is 2 days before the start and 2 days after the radioisotope studies, as well as with the use of iodine-containing contrast agents;
• Porphyria;
• Leukopenia;
• Infectious diseases, injuries, gangrene, extensive surgical interventions, severe blood loss, burns and other conditions that require insulin therapy;
• Period 2 days before and 2 days after any surgical intervention;
• Acute alcohol intoxication, alcoholism;
• Period of pregnancy and breastfeeding;
• Age up to 18 years;
• Compliance with low-calorie diet (less than 1000 calories per day);
• Dystrophic diseases (lipodystrophy, myotonic dystrophy);
• Lack of glucose-6-phosphate dehydrogenase;
• Hypersensitivity to the active or auxiliary components of the drug.

With caution Glibomet prescribed for:

• Thyroid disease;
• Decreased function of the anterior lobe of the pituitary or adrenal cortex;
• Febrile syndrome;

Glibomet is not recommended for use in patients over 60 years of age, whose work is associated with high physical exertion, since they have an increased risk of developing lactic acidosis.

Dosing and Administration

Glybomet is taken orally during a meal.

The dosage and duration of therapy are set by the attending physician individually, depending on the level of glucose in the blood and the state of carbohydrate metabolism.

The initial dose of Glibomet is 1-3 tablets per day, followed by adjustment in order to achieve the optimal level of glucose in the blood. Per day should not be used more than 6 tablets of the drug.

Side effects

The use of Glibomet can cause the following side effects from various systems of vital activity of the organism:

• Digestive system: nausea, vomiting, diarrhea, loss of appetite, metallic taste in the mouth, abdominal pain, increased activity of hepatic transaminases;
• The hematopoietic system: thrombocytopenia, leukopenia, erythrocytopenia, pancytopenia, megaloblastic or hemolytic anemia, agranulocytosis;
• Skin: skin rash, itching, erythema, urticaria, photosensitivity;
• Central nervous system: headache;
• Metabolism: lactic acidosis, hypoglycemia;
• Other side effects: while taking Glibomet with alcohol - disulfiram-like reaction, accompanied by symptoms such as redness of the skin of the face and upper half of the body, nausea, vomiting, headache, hypertension, palpitations.

Lactic acidosis and hypoglycemia may develop as a result of the use of Glibomet in excessive dosages.

Symptoms of lactic acidosis are:

• Respiratory disorders;
• Muscle pain;
• Weakness;
• Nausea and vomiting;
• Diarrhea;
• Hypothermia;
• Abdominal pain;
• Reflex bradyarrhythmia;
• Hypotension;
• Confusion and loss of consciousness.

Symptoms of hypoglycemia are:

• Weakness;
• Hunger;
• Sweating;
• Drowsiness;
• Feeling of fear;
• Palpitations;
• Tremor;
• Paresthesia in the mouth;
• Pallor of the skin;
• Violation of coordination of movements;
• Temporary neurological disorders.

If lactacidosis is suspected, use of Glibomet should be immediately stopped and the patient should be hospitalized. The most effective treatment for lactic acidosis is hemodialysis.

In case of unexpressed hypoglycemia, it is recommended to take something sweet (sugar, honey, jam, sweet tea). If there is a loss of consciousness, it is recommended to inject a 40% dextrose solution intravenously (40-80 ml) and infuse a solution of dextrose 5-10%

special instructions

During the period of treatment with glibomet patients should periodically check the level of creatinine in the serum.

While taking coumarin derivatives, inhibitors of MAO, phenylbutazone, sulfonamides, beta-blockers, ethanol, probenecid, sulfonamide, miconazole, cyclophosphamide, pheniramidol, salicylates, allopurinol, oxytetracycline, hypoglycemic activity increases.

With simultaneous use with oral contraceptives, adrenaline, barbiturates, thiazide diuretics, thyroid hormone preparations hypoglycemic effect of Glibomet decreases.

Analogs

Structural analogues of Glibomet are:

• Bagomet Plus;
• Gluconorm;
• Glucovans.

Terms and conditions of storage

According to the instructions, Glibomet stored in a dry, dark, out of reach of children. The shelf life of the drug is 3 years.